The Motley Fool
19 Jul 2026, 10:27 UTC · 20h ago
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
19 Jul 2026, 10:27 UTC · 20h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The iShares U.S. Pharmaceuticals ETF (IHE) is heavily concentrated in blue-chip pharmaceutical companies, with Johnson & Johnson and Eli Lilly comprising nearly 45% of the fund. — High concentration in two mega-cap pharma stocks makes the fund's performance highly sensitive to the specific clinical and regulatory outcomes of these two companies.
+0.30The VanEck Biotech ETF (BBH) focuses on high-growth, research-intensive biotech companies, resulting in higher price volatility tied to clinical trial results and regulatory decisions. — Biotech exposure increases portfolio risk-sensitivity and potential for sharp swings based on binary R&D outcomes.
+0.20IHE offers a dividend yield approximately one percentage point higher than that of BBH. — A higher yield makes the pharma ETF more attractive for income-seeking investors, slightly favoring it during periods of risk aversion.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Described as a proven, profitable drugmaker providing blue chip stability.
Highlighted as a proven, profitable drugmaker and a key driver of stability for IHE.
Mentioned as a top holding in a stable pharmaceutical ETF and recommended by The Motley Fool.
Mentioned as a top holding in a growth-focused biotech ETF and recommended by The Motley Fool.
Mentioned as a top holding in a growth-focused biotech ETF and recommended by The Motley Fool.
Mentioned as a top holding in a growth-focused biotech ETF and recommended by The Motley Fool.
[mutual] Both are identified as blue chip pharmaceutical companies within the same fund profile.
[mutual] Both are identified as blue chip pharmaceutical companies within the same fund profile.
[mutual] Both are identified as blue chip pharmaceutical companies within the same fund profile.
[mutual] Both are listed as top holdings in a biotech-focused ETF targeting genetic research and diagnostics.
[mutual] Both are listed as top holdings in a biotech-focused ETF targeting genetic research and diagnostics.
[mutual] Both are listed as top holdings in a biotech-focused ETF targeting genetic research and diagnostics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1h ago
